Related Experiment Videos
Paclitaxel in cancer therapy
Tarek M Mekhail1, Maurie Markman
1Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA. Mekhait@ccf.org
Expert Opinion on Pharmacotherapy
|May 31, 2002
Summary
Paclitaxel is a potent chemotherapy drug that disrupts microtubule dynamics for cancer cell death. Acquired resistance involves tubulin alterations and drug efflux pumps, with toxicities including hypersensitivity and neurotoxicity.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Paclitaxel is a powerful chemotherapeutic agent introduced in the last decade.
- It functions by promoting tubulin polymerization, disrupting microtubule dynamics essential for cell division and interphase.
- This mechanism leads to cancer cell death.
Purpose of the Study:
- To review the efficacy and mechanisms of action of paclitaxel.
- To discuss acquired resistance mechanisms to paclitaxel.
- To outline the toxicities and clinical applications of paclitaxel in various cancers.
Main Methods:
- Literature review of paclitaxel's mechanism of action.
- Analysis of studies detailing resistance pathways.
- Compilation of data on paclitaxel's toxicity profile and clinical activity.
Main Results:
- Paclitaxel effectively treats a wide range of cancers, including breast, ovarian, lung, and head and neck cancers.
- Resistance mechanisms include tubulin structure modification and enhanced drug efflux via phosphoglycoproteins.
- Common toxicities include hypersensitivity reactions, neurotoxicity, and hematological issues, often dose- and schedule-dependent.
Conclusions:
- Paclitaxel is a highly effective chemotherapeutic agent with broad anti-tumor activity.
- Understanding resistance mechanisms and managing toxicities are crucial for optimizing paclitaxel therapy.
- Paclitaxel remains a vital treatment option for numerous malignancies, including refractory and AIDS-associated cancers.